German biotech company Ariceum Therapeutics announced on Tuesday that it has received approval from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application to start a Phase I/II clinical trial (SANTANA-225) of its proprietary radiolabelled peptide, 225Ac-SSO110, in patients with small cell lung cancer (SCLC) or Merkel Cell Carcinoma (MCC).
A global, open-label Phase I/II study, SANTANA-225 is intended to evaluate the safety, tolerability, preliminary efficacy and recommended Phase II dose of 225Ac-SSO110 in patients with extensive-stage SCLC or MCC who are on first-line maintenance therapy with checkpoint inhibitors.
Ariceum Therapeutics is collaborating with its partners and clinical sites in the US and other countries to start recruitment of patients in the first quarter of 2025.
The product is being developed along with its companion patient selection tracer 68Ga-SSO120 as a 'theranostic pair' targeted radionuclide treatment of multiple indications expressing SSTR2, such as SCLC, MCC and other aggressive cancers.
Adicet Bio secures FDA Fast Track Designation for ADI-001 to treat refractory SLE
Acrivon Therapeutics receives FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Vistagen secures US patent for AV-101 in neuropathic pain treatment
Thermo Fisher Scientific launches international registry for adolescent alopecia areata
hVIVO successfully completes RSV antiviral trial for Shionogi
Valneva secures UK approval for world's first chikungunya vaccine
Alys Pharmaceuticals' IND for ALY-101 approved in US and Canada
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
NFL Biosciences confirms superior safety profile of NFL-101 in new toxicity study
Avirmax Biopharma completes first cohort of Wet AMD clinical trial
PhaseV collaborates with Alimentiv to address challenges in GI clinical trials
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Helix unveils clinico-genomic dataset of over 15,000 patients treated with GLP-1 agonists
Roquefort Therapeutics sells Lyramid for USD10.8m equity deal with Pleiades Pharma